Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 1, 2006, Pages 169-175

  Rensen, Patrick C N ^a,c   Sliedregt, Leo A J M ^a   Van Santbrink, Peter J ^a   Ferns, Michiel ^a   Schifferstein, Hendrik N J ^b   Van Leeuwen, Steven H ^a   Souverijn, John H M ^c   Van Berkel, Theo J C ^a   Biessen, Erik A L ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cholesterol lowering drugs; Hyperlipoproteinemia; Lipoproteins; Receptors; Transgenic models

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CHOLESTEROL; GLYCOLIPID; HYPOCHOLESTEROLEMIC AGENT; IODINE 125; ISOTOPE; LITHOCHOLIC OLEATE; N ACETYLGALACTOSAMINE; OLEIC ACID; SCAVENGER RECEPTOR BI; TYROSINE; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; DRUG DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LCO TYR GALNAC3; LCO-TYR-GALNAC3; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXHAUST GAS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER; LIVER CELL; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RECEPTOR AFFINITY; TRANSGENIC MOUSE; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; MACROPHAGE; METABOLISM; SPLEEN; SYNTHESIS;

ACETYLGALACTOSAMINE; ANIMALS; APOLIPOPROTEINS E; ASIALOGLYCOPROTEIN RECEPTOR; ATHEROSCLEROSIS; CHOLESTEROL; GLYCOLIPIDS; HYPERLIPIDEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; SPLEEN;

EID: 33644819313     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000193620.98587.40     Document Type: Article

References (29)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
4. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
5. Thompson GR, Barter PJ. Therapeutic approaches to reducing the LDL-and HDL-associated risks of coronary heart disease. Curr Opin Lipidol. 2000;11:567-570.
6. Rader DJ, Ikewaki K, Duverger N, Feuerstein I, Zech L, Connor W, Brewer HB. Jr. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993;342:1455-1458.
7. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071-2074.
8. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF Jr, Marcovina S, Brewer HB, Jr., Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3:744-749.
9. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999;274:2366-2371.
10. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000;20:721-727.
11. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol. 2000;11:627-637.
12. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531-554.
13. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry. 1990;29:10009-10018.
14. Baenziger JU, Maynard Y. Human hepatic lectin. Physiochemical properties and specificity. J Biol Chem. 1980;255:4607-4613.
15. van Berkel TJ, Kruijt JK, Spanjer HH, Nagelkerke JF, Harkes L, Kempen HJ. The effect of a water-soluble tris-galactoside-terminated cholesterol derivative on the fate of low density lipoproteins and liposomes. J Biol Chem. 1985;260:2694-2699.
16. Kempen HJ, Kuipers F, van Berkel TJ, Vonk RJ. Effect of infusion of "tris-galactosyl-cholesterol" on plasma cholesterol, clearance of lipoprotein cholesteryl esters, and biliary secretion in the rat. J Lipid Res. 1987;28:659-666.
17. Biessen EA, Bakkeren HF, Beuting DM, Kuiper J, Van Berkel TJ. Ligand size is a major determinant of high-affinity binding of fucose- and galactose-exposing (lipo)proteins by the hepatic fucose receptor. Biochem J. 1994;299:291-296.
18. Biessen EA, Vietsch H, Van Berkel TJ. Cholesterol derivative of a new triantennary cluster galactoside lowers serum cholesterol levels and enhances secretion of bile acids in the rat. Circulation. 1995;91:1847-1854.
19. Sliedregt LA, Rensen PC, Rump ET, van Santbrink PJ, Bijsterbosch MK, Valentijn AR, van der Marel GA, van Boom JH, van Berkel TJ, Biessen EA. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem. 1999;42:609-618.
20. Karayan L, Qiu S, Betard C, Dufour R, Roederer G, Minnich A, Davignon J, Genest J Jr. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene. Arterioscler Thromb. 1994;14:1258-1263.
21. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, Sirtori CR. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis. 1995;117:189-198.
22. Rensen PC, van Leeuwen SH, Sliedregt LA, van Berkel TJ, Biessen EA. Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J Med Chem. 2004;47:5798-5808.
23. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975;65:42-49.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Polin phenol reagent. J Biol Chem. 1951;193:265-275.
25. Rensen PC, Jong MC, van Vark LC, van der Boom H, Hendriks WL, van Berkel TJ, Biessen EA, Havekes LM. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem. 2000;275:8564-8571.
26. Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res. 1997;38:1070-1084.
27. Tozawa R, Ishibashi S, Osuga J, Yamamoto K, Yagyu H, Ohashi K, Tamura Y, Yahagi N, Iizuka Y, Okazaki H, Harada K, Gotoda T, Shimano H, Kimura S, Nagai R, Yamada N. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit. Its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem. 2001;276:12624-12628.
28. Ashwell G, Kawasaki T. A protein from mammalian liver that specifically binds galactose-terminated glycoproteins. Methods Enzymol. 1978;50:287-288.
29. Rensen PC, Sliedregt LA, Ferns M, Kieviet E, van Rossenberg SM, van Leeuwen SH, van Berkel TJ, Biessen EA. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem. 2001;276:37577-37584.